Nuvectis licenses ex-China rights to Haisco’s NXP100, NXP200 in deal worth up to USD 1.42 billion

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

NVCT

0.00
  • Nuvectis signed a license deal with Haisco for exclusive ex-China rights to two clinical-stage assets, shifting its focus toward late-stage development.
  • Upfront and near-term payments total up to USD 40 million; Haisco can earn up to USD 1.421 billion in milestones plus tiered royalties.
  • The portfolio adds NXP100, an oral once-daily complement factor B inhibitor with two PNH MAAs under review in China.
  • The deal also brings in NXP200, an oral paradox-breaker BRAF inhibitor in Phase 1b in China, including reported activity in CNS tumors.
  • Closing is subject to financing conditions requiring Nuvectis to secure sufficient capital to develop the licensed products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220730PRIMZONEFULLFEED9750304) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.